A limiting factor in the efficacy of bioartificial liver (BAL) for the treatment of liver failure is the toxicity of the patients’ serum to the hepatocytes in the device. This study investigates the interaction of liver cancer patient serum with primary and immortalised rat hepatocytes. Liver cancer serum increased the growth rate of immortalised hepatocytes, without affecting reduced glutathione levels. The activities of DT-diaphorase and pi glutathione-S-transferase (GST), enzymes associated with de-differentiation, were also increased. Exposure of primary hepatocytes to liver cancer serum resulted in a decrease in cytochrome P450 (CYP) content, and in P450 dependent metabolism of testosterone. Formation of 2-alpha- and 6-beta- hydroxy testosterone was decreased. These reactions are predominantly associated with CYP 2C11 and 3A1 respectively in normal rat liver. The activity of total GST was also decreased, although that of the pi isoenzyme of GST was not affected. Our results suggest that exposure of hepatocytes in a bioreactor to liver cancer patient serum will result in overgrowth of cells, if proliferating cells are being used, and in de-differentiation. The serum may have to be pretreated with adsorbants to remove toxins prior to BAL treatment.
SussmanN.L., GislasonG.T., ConlinC.A., KellyJ.H.. The Hepatix extracorporeal liver assist device: Initial clinical experience. Int J Artif Organs1994; 18: 390–6.
2.
EllisA.J., HughesR.D., WendonJ.A.Pilot-controlled trial of the extracorporeal liver assist device in acute liver failure. Hepatology1996; 24: 1446–51.
3.
WatanabeF.D., MullonC J-P, HewittW.R.Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial. Ann Surg1997; 225: 484–94.
4.
ChenS.C., MullonC., KahakuE.Treatment of severe liver failure with a bioartificial liver. Ann NY Acad Sci1997; 831: 350–60.
GerlachJ., TrostT., RyanC.J.Hybrid liver support system in a short term application on hepatectomised pigs. Int J Artif Organs1994; 17: 549–53.
7.
FlendrigL.M., Di FlorioE., ManciniA.In vivo investigation of a novel bioartificial liver (BAL) based on porcine hepatocytes. Hepatology1997; 26: 168A.
8.
RozgaJ., DemetriouA.A.. Development and testing of a bioartificail liver. In: BerryM.N., EdwardsA.M., eds. The hepatocyte review.The Netherlands: Kluwer Academic Publishers, 2000, 543–59.
MelkonianA.D., GaylorJ.D.S., CousinsR.B., GrantM.H.. Culture of a differentiated liver cell line, Hep G2, in serum with application to a bioartificial liver: Effect of supplementation of serum with amino acids. Int J Artif Organs1994; 18: 611–7.
11.
ShiQ., GaylorJ.D.S., CousinsR.B., PlevrisJ., HayesP.C., GrantM.H.. The effects of serum from patients with acute liver failure on the growth and metabolism of Hep G2 cells. Int J Artif Organs1998; 22: 1023–30.
12.
CunninghamJ.M., HodgsonH.J.F.. Microcarrier culture of hepatocytes in whole plasma for use in liver support bioreactors. Int J Artif Organs1992; 15: 162–7.
13.
HughesR.D., CochraneA.M.G., ThomsonA.D., Murray-LyonI.M., WilliamsR.. The cytotoxicity of plasma from patients with acute hepatic failure to isolated rabbit hepatocytes. Br J Exp Pathol1976; 57: 348.
14.
GoverC.D., HughesR.D., WilliamsR.. Rapid inhibition of DNA synthesis in hepatocytes from regenerating livers by serum from patients with fulminant hepatic failure. Br J Exp Pathol1982; 63: 547–53.
15.
UchinoJ., MatsueH., TakahashiM.A hybrid artificial liver system. Function of cultured monolayer pig hepatocytes in plasma from hepatic failure patients. ASAIO Trans1991; 37: M337–8.
16.
EkevallE., PlevrisJ., SmithM.D.Response of rat hepatocytes in culture to serum from fulminant hepatic failure patients. Int J Artif Organs1997; 21: 204.
17.
SakaiY., NaruseK., NagashimaI., MutoT., SuzukiM.. In vitro function of porcine hepatocyte spheroids in 100% human plasma. Cell Transplant1996; 5: 41.
18.
MatthewH.W.T., SternbergJ., StefanovichP.Effects of plasma exposure on cultured hepatocytes: implications for bioartificial liver support. Biotech Bioeng1996; 51: 100.
19.
MacDonaldC., WillettB.. The immortalisation of rat hepatocytes by transfection with SV40 sequences. Cytotechnology1997; 23: 161–70.
20.
MacDonaldC., VassM., WillettB., ScottA., GrantM.H.. Expression of liver functions in immortalised rat hepatocyte cell lines. Human Exper Toxicol1994; 13: 439–44.
21.
AndersonK., AndrewsR., YinL.Cytotoxicity of xenobiotics and expression of glutathione-S-transferases in immortalised rat hepatocyte cell lines. Human Exper Toxicol1998; 17: 131–7.
22.
GrantM.H., AndersonK., McKayG.C., WillsM., HendersonC., MacDonaldC.. Manipulation of the phenotype of immortalised rat hepatocytes by different culture configurations and by dimethylsulphoxide. Human Exper Toxicol2000; 19: 309–17.
23.
AndersonK., YinL., MacDonaldC., GrantM.H.. Immortalized hepatocytes as in vitro model systems for toxicity testing: the comparative toxicity of menadione in immortalized cells, primary cultures of hepatocytes and HTC hepatoma cells. Toxicol in Vitro1996; 10: 721–7.
24.
HendrichS., PitotH.C.. Enzymes of glutathione metabolism as biochemical markers during hepatocarcinogenesis. Cancer Metast Rev1987; 6: 155–78.
25.
SchlagerJ.J., PowisG.. Cytosolic NAD(P)H: (quinone acceptor) oxidoreductase in human normal and tumour tissue: effects of cigarette smoking and alcohol. Int J Cancer1990; 45: 403–9.
26.
SchorN.A., OgawaK., LeeG., FarberE.. The use of DT-diaphorase for the detection of foci of early neoplastic transformation in rat liver. Cancer Letts1978; 5: 167–71.
27.
WortelboerH.M., de KruifC.A., van IerselA.A.J., FalkeH.E., NoordhoekJ., BlaauboerB.J.. The isoenzyme pattern of cytochrome P450 in rat hepatocytes in primary culture, comparing different enzyme activities in microsomal incubations and in intact monolayers. Biochem Pharmacol1990; 40: 2525–34.
28.
MoldeusP., HogbergJ., OrreniusS.. Isolation and use of liver cells. Meth Enzymol1978; 52: 60–71.
29.
ElsdaleT., BardJ.. Collagen substrata for studies on cell behaviour. J Cell Biol1972; 54: 626–37.
30.
HissinP.J., HilfR.. A fluorimetric method for the determination of oxidised and reduced glutathione in tissues. Anal Biochem1976; 74: 214–26.
31.
LowryO.H., RosebroughN.J., FarrA.L., RandallR.J.. Protein measurement with the Folin phenol reagent. J Biol Chem1951; 193: 265–75.
32.
LindC., HojebergB.. Biospecific absorption of hepatic DT-diaphorase on immobilised dicoumarol. Archiv Biochem Biophys1981; 270: 217–24.
33.
HabigW.H., JakobyW.B.. Assays for the differentiation of glutathione-S-transferase. Meth Enzymol1981; 77: 398–405.
34.
OmuraT., SatoR.. Carbon-monoxide binding pigment of liver microsomes: evidence for its haemoprotein nature. J Biol Chem1964; 239: 2379–85.
35.
WattsP., SmithM.D., EdwardsI., ZammitV., BrownV., GrantM.H.. The influence of medium composition on the maintenance of cytochrome P450, glutathione content and urea synthesis: a comparison of rat and sheep primary hepatocyte cultures. J Hepatol1995; 23: 605–12.
36.
MooneyD., HansenL., VacantiJ.Switching from differentiation to growth in hepatocytes: control by extracellular matrix. J Cell Physiol1992; 151: 497–505.
37.
McGowanJ.A.. Reciprocal regulation of adult rat hepatocyte growth and functional activities in culture by dimethylsulphoxide. J Cell Physiol1988; 137: 497–504.
38.
SchenkmanJ.B., ThummelK.E., FaureauL.V.. Physiological and pathophysiological alterations in rat hepatic cytochrome P450. Drug Metab Rev1989; 20: 557–84.
39.
KernA., BaderA., PichmayrR., SewingK-F. Drug metabolism in hepatocyte sandwich cultures of rats and humans. Biochem Pharmacol1997; 54: 761–72.
40.
IberH., MorganE.T.. Regulation of hepatic cytochrome P450 2C11 by transforming growth factor-β, hepatocyte growth factor, and interleukin-11. Drug Metab Dispos1998; 26: 1042–4.
41.
HughesR.D., ZhangL., TsubouchiH., DaikuharaY., WilliamsR.. Plasma hepatocyte growth factor and biliprotein levels and outcome in fulminant hepatic failure. J Hepatol1994; 20: 106–11.
